Drug Profile
Research programme: sarcoplasmic reticulum calcium transporting ATPase 2b isoform modulators - Eiger BioPharmaceuticals Inc
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Celladon
- Class Small molecules
- Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Diabetes mellitus; Neurodegenerative disorders
Most Recent Events
- 07 Aug 2015 Research programme: sarcoplasmic reticulum calcium transporting ATPase 2b isoform modulators - Celladon is available for licensing as of 26 Jun 2015. www.celladon.com
- 26 Jun 2015 Suspended - Preclinical for Diabetes mellitus in USA (unspecified route)
- 26 Jun 2015 Suspended - Preclinical for Neurodegenerative disorders in USA (unspecified route)